Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Pulls The Plug On PPAR Candidate After Carcinogenicity Tests

Executive Summary

Roche will continue to dedicate R&D resources toward the development of diabetes drugs despite the fact the company has decided not to pursue development of R483, its Phase II insulin sensitizer, Pharma CEO William Burns said

You may also be interested in...



Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus

Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24

Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus

Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24

Rituxan RA Approval Raises The Stakes, But With A Lower Price

Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel